BLCO Stock Chart & Stats
C$23.82
C$0.30(1.32%)
At close: 4:00 PM EDT
C$23.82
C$0.30(1.32%)
Day’s Range― - ―
52-Week RangeC$19.36 - C$25.70
Previous CloseN/A
Volume101.00
Average Volume (3M)1.51K
Market Cap
C$8.38B
Enterprise ValueC$10.72K
Total Cash (Recent Filing)C$367.00M
Total Debt (Recent Filing)C$5.12B
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Nov 04, 2026EPS Estimate
0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding357,165,250
10 Day Avg. Volume933
30 Day Avg. Volume1,507
Financial Highlights & Ratios
PEG Ratio-1.26
Price to Book (P/B)0.94
Price to Sales (P/S)1.18
P/FCF Ratio-91.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$28.18Price Target Upside18.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)1.11
Revenue Forecast (FY)C$7.69B
Bulls Say, Bears Say
Bulls Say
Broad-based Revenue GrowthGrowth across all three operating segments reduces reliance on a single product category and indicates broad customer demand. Continued expansion in pharmaceuticals, surgical products, and vision care can support durable revenue momentum and improve operating leverage over the next several quarters.
Margin And Cash-flow ImprovementHigher gross margins and productivity gains show that the company is converting product mix and operational improvements into stronger profitability. Combined with improving cash generation, this creates more internal funding capacity for research, investment, and debt reduction.
Strengthening Premium Product MixRapid adoption of premium intraocular lenses can improve mix quality and raise revenue per procedure in the Surgical segment. A larger differentiated portfolio may strengthen competitiveness, support margin expansion, and provide a durable growth avenue beyond basic procedure volumes.
Bears Say
Elevated Leverage And Interest BurdenAlthough leverage has improved, debt remains substantial relative to operating earnings and interest expense absorbs significant cash resources. This limits financial flexibility, makes deleveraging dependent on sustained execution, and can constrain investment or resilience if operating conditions weaken.
Persistent Net LossesThe company has not yet translated revenue growth and healthy gross margins into consistent bottom-line profitability. Continued net losses weaken returns on equity, reduce earnings-based financial flexibility, and leave performance more exposed to interest costs and non-operating pressures.
Pipeline And Regulatory Execution RiskSeveral future growth opportunities depend on clinical results, regulatory submissions, and approval timing rather than established commercial performance. Delays or unsuccessful programs could defer expected product contributions, reduce returns on R&D, and make the growth plan less predictable.
Bausch + Lomb Corporation News
BLCO FAQ
What was Bausch + Lomb Corporation’s price range in the past 12 months?
Bausch + Lomb Corporation lowest stock price was C$19.36 and its highest was C$25.70 in the past 12 months.
What is Bausch + Lomb Corporation’s market cap?
Bausch + Lomb Corporation’s market cap is C$8.38B.
When is Bausch + Lomb Corporation’s upcoming earnings report date?
Bausch + Lomb Corporation’s upcoming earnings report date is Nov 04, 2026 which is in 45 days.
How were Bausch + Lomb Corporation’s earnings last quarter?
Bausch + Lomb Corporation released its earnings results on Jul 29, 2026. The company reported C$0.209 earnings per share for the quarter, missing the consensus estimate of C$0.214 by -C$0.006.
Is Bausch + Lomb Corporation overvalued?
According to Wall Street analysts Bausch + Lomb Corporation’s price is currently Undervalued.
Does Bausch + Lomb Corporation pay dividends?
Bausch + Lomb Corporation does not currently pay dividends.
What is Bausch + Lomb Corporation’s EPS estimate?
Bausch + Lomb Corporation’s EPS estimate is 0.29.
How many shares outstanding does Bausch + Lomb Corporation have?
Bausch + Lomb Corporation has 357,165,250 shares outstanding.
What happened to Bausch + Lomb Corporation’s price movement after its last earnings report?
Bausch + Lomb Corporation reported an EPS of C$0.209 in its last earnings report, missing expectations of C$0.214. Following the earnings report the stock price went down -2.394%.
Which hedge fund is a major shareholder of Bausch + Lomb Corporation?
Currently, no hedge funds are holding shares in TSE:BLCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bausch + Lomb Corporation Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$28.18 (18.30% Upside)
C$28.18 (18.30% Upside)
Blogger Sentiment
Bullish
TSE:BLCO Sentiment 60%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth C$1.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.20%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Bausch + Lomb Corporation
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
BLCO Company Deck
BLCO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum across revenue, margin expansion, cash generation and deleveraging. Broad-based growth across segments (Pharmaceuticals, Surgical, Vision Care), robust adjusted EBITDA growth, raised guidance and continued R&D investment were emphasized as evidence that the three-year plan is on track. Notable risks include elevated leverage and interest expense, macro/currency sensitivity (consumer demand tied to gas prices), ongoing regional disruptions (e.g., strikes), competitive dynamics in surgical and dry eye markets, and several important clinical and regulatory milestones still pending. Overall, the positives in growth, margins, cash flow and guidance upgrades substantially outweigh the outlined risks.View all TSE:BLCO earnings summariesBLCO Stock 12 Month Forecast
Average Price Target
C$28.18
▲(18.30% Upside)
Technical Analysis
AptarGroup
―
Baxter International
―
Cooper Co
―
Staar Surgical
―
West Pharmaceutical Services
―